{"entity":{"id":"nct06854445","kind":"trial","name":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Gemcitabine, Oxaliplatin and TQB2825 in non-Hodgkin lymphoma, run by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., now recruiting.","summary":"Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma is a phase 2 interventional study registered as NCT06854445 by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., with 55 participants planned, started 2025-03-12 and due to reach its primary completion in 2025-10. Interventions recorded: TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06854445","url":"https://clinicaltrials.gov/study/NCT06854445"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine","oxaliplatin","tqb2825"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06854445","phase":"2","setting":"Phase II Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","enrolled":55,"outcomes":[]},"route":"/trials/nct06854445/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"oxaliplatin","kind":"drug","name":"Oxaliplatin","route":"/drugs/oxaliplatin/"},{"id":"tqb2825","kind":"drug","name":"TQB2825","route":"/drugs/tqb2825/"}]}}